National Cancer Institute Selects Open Biosystems To Validate Gene Silencing Capability Of shRNAmir Clones
HUNTSVILLE, Ala.--(BUSINESS WIRE)--Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, has been selected by the National Cancer Institute (NCI) to verify the effectiveness of lentiviral microRNA-adapted short hairpin RNA (shRNAmir) technology in 135 specifically targeted cancer genes.